Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Comparison of pharmacokinetics and safety of fixed-dose versus loose combination of atorvastatin/fenofibrate 10/145 mg in healthy Korean participants.

Translational and clinical pharmacology·2026
Same authorSame journal

Implementation of decentralized clinical trials in Korea from a resource-based perspective.

Translational and clinical pharmacology·2026
Same author

Pioneering a Hybrid Decentralized Clinical Trial in South Korea: Assessing Feasibility, Data Integrity, and Participant Perceptions.

Clinical and translational science·2026
Same author

Clinical Impact of Maximum Plasma Concentration of Busulfan in Pediatric Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation.

Clinical pharmacology and therapeutics·2026
Same author

Safety, pharmacokinetics and pharmacodynamics of NXC736, a novel sphingosine-1-phosphate receptor modulator.

British journal of clinical pharmacology·2026
Same author

Pharmacokinetic Drug-Drug Interactions of DA-8010 with Clarithromycin or Rifampicin: Influence of CYP2D6 Phenotype on the Extent of These Interactions.

Drug design, development and therapy·2026

Related Experiment Video

Updated: Jul 9, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Development and evaluation of automated screening algorithms for pre-analytical errors in pharmacokinetic data: a

Minsub Shim1, Jaegu Kang1, Kyung-Sang Yu1

  • 1Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Korea.

Translational and Clinical Pharmacology
|July 8, 2026
PubMed
Summary

Automated methods can detect pre-analytical errors in pharmacokinetic data. A Mahalanobis distance-based approach significantly outperformed a run-test method in identifying sample mix-ups, ensuring data integrity.

Keywords:
AlgorithmsMonte Carlo MethodPharmacokineticsQuality Control

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Related Experiment Videos

Last Updated: Jul 9, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Area of Science:

  • Pharmacokinetics and Pharmacometrics
  • Clinical Pharmacology
  • Data Quality Assurance

Background:

  • Pre-analytical errors, such as sample mix-ups, can severely compromise pharmacokinetic (PK) data integrity.
  • Ensuring the accuracy of PK data is crucial for reliable clinical pharmacology research and drug development.
  • Existing methods for detecting pre-analytical errors in PK datasets may lack sufficient sensitivity or specificity.

Purpose of the Study:

  • To develop and validate automated methods for detecting pre-analytical errors in simulated pharmacokinetic data.
  • To compare the performance of a Mahalanobis distance-based method against a traditional run-test method.
  • To assess the robustness of these methods under various challenging conditions, including different PK models and data imperfections.

Main Methods:

  • Simulated vancomycin PK data were generated and intentionally corrupted with two types of pre-analytical errors: time point swaps (TS) and concentration swaps (CS).
  • Two automated detection approaches were developed: a run-test non-parametric method and a Mahalanobis distance-based method employing leave-one-out cross-validation (LOOCV).
  • Performance was evaluated on 12,500 simulated PK profiles, comparing error detection rates, specificity, precision, recall, and area under the ROC curve (AUC).

Main Results:

  • The Mahalanobis distance-based method demonstrated a significantly higher error detection rate (79.7%) compared to the run-test method (59.6%, p < 0.001).
  • The distance-based method achieved a superior AUC (0.856 vs. 0.574) and better recall for TS errors (80.4% vs. 71.9%) and precision for CS errors (86.1% vs. 59.8%).
  • Detection performance remained robust across alternative population PK models, a different drug (theophylline), contaminated training sets, missing data, and sampling time variations.

Conclusions:

  • The Mahalanobis distance-based method with LOOCV is a more effective tool for identifying pre-analytical errors in PK datasets than the conventional run-test method.
  • This distance-based approach offers a practical and reliable quality control solution for enhancing the integrity of pharmacokinetic data in research.
  • Implementing such automated detection tools is vital for ensuring the accuracy and validity of findings in clinical pharmacology.